Navigation Links
ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
Date:5/14/2009

FREDERICK, Md., May 14 /PRNewswire/ -- ImQuest Bio and Arisyn jointly presented important new results on ATI-0810 (Formerly PG301029), a novel late stage inhibitor of hepatitis C virus (HCV) replication, at the 13th ISVHLD meeting held last week in Washington D.C. The presentation highlighted the ability of PG301029 to potently suppress the replication of HCV in vitro and defined its potential mechanism of antiviral action through the selection of a replicon resistant to the antiviral effects of the compound. Resistant HCV replicon sequences were selected in cell culture and resulted in mutations in the viral NS5A proximal to the NS5A-NS5B cleavage junction. The defined mutation would affect viral polyprotein processing at this site, or the interaction of NS5A, or the NS5A/5B polyprotein(s) with host cell factors involved in viral RNA replication, either of which presents a novel target for antiviral therapy. Todd B. Parsley, Ph.D., Director of Hepatitis Virus Research, presented the new findings which also included gene profiling patterns in compound treated and untreated cells. The studies included ImQuest co-authors Lu Yang, MD and Robert W. Buckheit, Jr., Ph.D.

"The data presented indicate that PG301029 has a unique mechanism of action as an inhibitor of hepatitis C virus replication," said the study's Principal Investigator, Dr. Parsley. "The genetic analysis suggests that PG301029 functions through a novel antiviral target, and we are excited about the prospects for exploiting this target for the development of new and potent anti-HCV therapies."

The presentation represents a continuation of the research partnership between ImQuest and Arisyn for the development of Arisyn's portfolio of antiviral and anticancer products based on its platform technology involving targeting of RNA transcription. Funding for the study was obtained in part from a Small Business SBIR grant recently awarded to ImQuest by th
'/>"/>

SOURCE ImQuest BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
2. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
3. ImQuest Presentations at Keystone Symposium Focus on Advancements in Their Therapeutic and Microbicide Development Programs
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
6. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... In the April issue of Experimental Biology ... by Drs. Rex Gaskins and Paul Kenis in ... campus of the University of Illinois Urbana-Champaign describe ... reduction-oxidation reactions underlie a variety of cell functions ... to these crucial roles in regulating normal cellular ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
(Date:4/17/2014)... A. Arias, M.D., Ph.D., at The University of Texas ... new superbug that caused a bloodstream infection in a ... issue of The New England Journal of Medicine ... class of highly-resistant bacteria known as methicillin-resistant Staphylococcus ... of hospital and community-associated infections. The superbug has also ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:New MRSA superbug emerges in Brazil 2
... ... care than other nations. Low back pain is the number two most common reason Americans ... spinal issues will now be able to see, touch and thereby better understand common spinal ... Issaquah, WA ...
... new study finds that Hispanics live in areas ... for colorectal cancer screening. Published early online in ... American Cancer Society, the study indicates that differences ... explain why Hispanics are less likely to undergo ...
... Atomic Force Microscope depicts on its screen the few ... flexible sticks, crisscrossing the surface on which they are ... in fact that they can self assemble into complex ... and University of Fribourg have teamed up to take ...
... SCD Probiotics ... to bring aid to the people of Chile. Donations are currently being raised to ... Valparaiso where it will be used and distributed, primarily through the Chilean military., , ... (PRWEB) April 11, 2010 -- In ...
... boosts performance, study finds , FRIDAY, April 9 (HealthDay ... medication react more like other children when faced with ... researchers have found. , The findings, published in the ... that the medication does what it,s supposed to do: ...
... ... in the state, Dr. Jeffrey Raval has pioneered a new process to make the injections ... fillers, a practice that the FDA approved in 2009. , ... Denver, Colo. (PRWEB) April 10, 2010 -- As an injector ...
Cached Medicine News:Health News:Latest Resource From Dynamic Disc Designs Helps Physicians Educate Patients 2Health News:Latest Resource From Dynamic Disc Designs Helps Physicians Educate Patients 3Health News:Hispanics live in areas with limited capacity for colorectal cancer screening 2Health News:The assembly of protein strands into fibrils 2Health News:Beneficial Microorganisms Rescue Chilean Earthquake Victims 2Health News:Beneficial Microorganisms Rescue Chilean Earthquake Victims 3Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 2Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 3
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... 14, 2007-Acceleron Pharma, Inc., a,biopharmaceutical company developing ... cancer-related diseases, today,announced results of a preclinical ... the compound to increase muscle mass,and strength ... of muscular,dystrophy. ACE-031 inhibits negative regulators of ...
... Biotechnology reports positive results from placebo,controlled phase ... dust,mite allergy , ,SCHLIEREN (Zurich), Switzerland, May ... today positive results from a multi-centre,and placebo-controlled ... an immunotherapeutic product candidate for the,treatment of ...
Cached Medicine Technology:Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in,Preclinical Studies 2Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in,Preclinical Studies 3Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 2Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 3Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 4Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 5Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 6Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 7
1 mm wide by 28 mm long sterling silver blade. Flat serrated handle with polished finish....
Lasik spatula useful for protecting a previous flap for retreatment to lift and smooth the corneal flap....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 150o....
Angled blade and flat serrated handle with polished finish. Blade: 1 mm x 10 mm....
Medicine Products: